



PRESS RELEASE

SimuGen Raises Series A Round Venture Capital and Angel Investment Funding

6 September 2010. London (UK) and Kuala Lumpur (Malaysia)

SimuGen, a pharmacogenomics company focused on predicting human toxicity early on in drug discovery, announced today that it has secured a Series A round of venture capital and Angel investment funding. The venture funding comes from a further investment by Kumpulan Modal Perdana (KMP) based in Kuala Lumpur, Malaysia. Previous funding commitments were through KMP and Business Angels as well as Malaysian and UK Government grants.

“We very much appreciate the continuous support of our current venture investors and welcome the new Angel investors on board to join us in our exciting journey to further commercialise SimuGen’s groundbreaking science-driven drug discovery software tool,” said Matthijs van Leeuwen, SimuGen’s Co-founder & COO. “The funding will be used to launch our flagship software product (HT-Stream) and to quickly grow into a sustainable business with a global reach”.

Dr Brian O’Keeffe, CEO of SimuGen, commented, “SimuGen has reached a most important stage in its development as we now go to market, with our flagship product capable of seamlessly analysing traditional ‘omic’ and High Content Screening (HCS) data, utilising our brand new software HT-Stream. Much of the interest shown by the industry is generated by a combination of disenchantment with existing toxicity testing and the urgency which the industry must apply to improving poor productivity and stock market sentiment. Data-rich decision-making is the key to the future of drug discovery and development at all stages, not least the assessment of toxicity. SimuGen, through the launch of our new HT-Stream software, brings this new data dimension right into the laboratories of all companies involved in the delivery of new, affordable and safe medicines to patients.”

About SimuGen

SimuGen is a venture-backed discovery pharmacogenomics company focused on predicting human toxicity early on in drug development. The company combines groundbreaking human cell and genomic modelling to produce high throughput screens for use alongside other early ADME testing. SimuGen’s software (HT-Stream) provides answers to three important questions that guide decisions around a lead compound:

1. what toxicities does it produce?
2. how toxic is it?
3. what could be done to make it less toxic?

HT-Stream can predict a wide spectrum of human liver safety concerns, a leading problem stifling drug innovation. However, the basic approach can assess multiple-organ toxicities.

Asia Pacific

Unit T108, Suite 7.01, Level 7
The Gardens South Tower
Mid Valley City
59200 Kuala Lumpur, Malaysia
T +603 2264 5200
F +603 2264 5201

Europe

Suite 405
International House
1- 6 Yarmouth Place
London W1J 7BU
United Kingdom
T +44 (0)2033 264 283

info@simugen-global.com | www.simugen-global.com